About Aditi Ganguly
Aditi is an experienced content developer and financial writer who is passionate about helping investors understand the do's and don'ts of investing. She has a keen interest in the stock market and has a fundamental approach when analyzing equities.
Aditi's fascination with the stock market began in college, where she majored in Economics, while researching The Great Recession for her thesis. After graduating, she began her career handling the content requirements for the mutual fund aggregator Groww. Since then she has become a financial journalist that focuses on writing articles that educate retail investors about the equity markets and the global economy.
Recent Articles By Aditi Ganguly
Advance Auto Parts: Buy or Sell in 2022?
Shares of leading auto parts manufacturer Advance Auto Parts (AAP) have seen double digit percentage price gains over the past year, thanks to the bullish investor sentiment surrounding the industry. But, with surging market volatility amid heightened geopolitical tensions, is AAP an ideal investment bet now? Read on to learn our view.
Should You Scoop Up Shares of Best Buy on the Dip?
Shares of technology products retailer Best Buy (BBY) have been foundering this year due to the broader market correction and tech rout. With surging market volatility amid worsening Russia-Ukraine hostilities, will BBY be able to regain its momentum soon? Read more to learn our view.
Home Depot: Buy, Sell, or Hold?
The price of shares of S&P 500 company Home Depot (HD) have been foundering lately due to the broader market pullback and its bleak short-term growth prospects. And because the markets remain volatile amid increased geopolitical tensions, the question is will HD be able to regain forward momentum soon? Read more to learn our view.
Is Aerojet Rocketdyne Holdings Stock a Buy or Sell?
The shares of leading aerospace and defense equipment manufacturer Aerojet Rocketdyne Holdings (ARJD) have gained momentum over the past few days as war has broken out between Russia and Ukraine. However, because the company’s proposed merger with Lockheed Martin (LMT) fell through, will it be able to maintain its growth trajectory over the long term? Read on.
Is Global Payments a Smart Fintech Stock to Buy?
Fortune 500 fintech company Global Payments (GPN) has been benefiting from changing payment technology trends. The company reported its best quarterly performance in its fiscal year 2021 fourth quarter, ended December 31. However, given dizzying market volatility amid worsening geopolitical tensions, will GPN be able to sustain its growth trajectory in the near term? Read more to learn our view.
Does Schneider National Stock Deserve a Place in Your Portfolio?
Leading transportation and logistics services provider Schneider National (SNDR) has benefited from increased freight transportation demand amid ongoing supply chain headwinds to achieve record-high earnings in its fiscal year 2021. But will the company be able to maintain this growth trajectory in the coming months? Read more to find out.
Does Fidelity National Information Services Deserve a Place in Your Portfolio?
Shares of Fortune 500 company Fidelity National Information Services (FIS) have slumped in price in double digits so far this year due to the broader market weakness. Given the surging market volatility and operational risks faced by the company, will FIS’ stock be able to regain momentum soon? Read more to find out.
Down More Than 80% in the Past Year, is Now a Good Time to Scoop Up Shares of Team Inc.?
Shares of the asset performance assurance provider Team, Inc. (TISI) have tumbled more than 85% in price over the past year due to the company’s weak operational performance and bleak growth prospects. So, amid surging market volatility and continued macroeconomic headwinds, will the stock be able to regain momentum soon? Read more to learn what we think.
Should You Buy Novavax on the Dip?
Leading biotech company Novavax (NVAX) has received temporary approvals for the use of its COVID-19 vaccine from several countries and has filed for emergency use authorization from the U.S. FDA. However, with several high-efficacy vaccines already available in the market, will NVAX be able to successfully commercialize its COVID-19 vaccine candidate? Read more to learn our view.